Anna Maria Pisacreta

Anna Maria Pisacreta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
APAnna Maria Pisacreta
Anna Maria Pisacreta
RMRuggiero Mascolo
Ruggiero Mascolo
MNMariangela Nivuori
Mariangela Nivuori
CDCostanza Caccia Dominioni
Costanza Caccia Dominioni
CGClaudia Gabiati
Claudia Gabiati
ABAntonio Brucato
Antonio Brucato

17 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
CACarlo Alfieri
Carlo Alfieri
ECEdoardo Campioli
Edoardo Campioli
PFPaolo Fiorina
Paolo Fiorina
EOEmanuela Orsi
Emanuela Orsi
VGValeria Grancini
Valeria Grancini
GCGiuseppe Castellano
Giuseppe Castellano
This study aimed to investigate the prevalence and determinants of glucose metabolism abnormalities and their impact on long-term clinical outcomes in kidney transplant recipients (KTxps). A retrospective analysis of 832 KTxps (2004–2020) was performed. Patients were assessed at 1 (T1), 6 (T6), and 12 (T12) months post-transplantation and clinically followed for an average of 103 ± 60 months. At T6, 484 patients underwent an oral glucose tolerance test for the diagnosis of alterations in glucose metabolism (AMG+) or post-transplant diabetes mellitus (PTDM+). The prevalence of pre-transplant diabetes was 6.2%, with 22.4% of PTDM+ within the 1st year. Patients with AMG were older and exhibited altered lipid profiles, higher body mass index, and increased inflammatory indices. Age at transplantation, lipid profile, and inflammatory status were significant determinants of PTDM. Graft loss was unaffected by glucose metabolism alterations. Survival analysis demonstrated significantly worse long-term survival for KTxps with diabetes (pre- and PTDM+, p = 0.04). In a comparison of the ND and PTDM+ groups, no significant differences in death with a functioning graft were found. The AMG+ group exhibited worse survival (p < 0.001) than AMG−, even after excluding patients with diabetes mellitus. Future randomized controlled trials are necessary to delve deeper into this subject, specifically examining the effects of new antidiabetic treatments.

1 July 2024 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
CACarlo Alfieri
Carlo Alfieri
PMPaolo Molinari
Paolo Molinari
SVSimone Vettoretti
Simone Vettoretti
MFMaria Fusaro
Maria Fusaro
JBJordi Bover
Jordi Bover
GCGiuseppe Castellano
Giuseppe Castellano
Chronic kidney disease (CKD) poses a significant epidemiological challenge, necessitating effective patient management strategies. Nutritional intervention, particularly vitamin D supplementation, has garnered attention for its potential therapeutic utility in CKD. Despite widespread acknowledgment of the importance of vitamin D, particularly in bone and mineral metabolism, its supplementation in CKD patients for non-skeletal purposes remains contentious due to limited evidence. Hypovitaminosis D linked with CKD substantially contributes to disturbances in mineral and bone metabolism, increasing the risks of cardiovascular complications and skeletal disorders. Notably, CKD patients experience progressive vitamin D deficiency, exacerbating as the disease progresses. Guidelines recommend monitoring 25-hydroxyvitamin D (25 (OH)-D) levels due to their correlation with mineral metabolism parameters, although robust evidence for recommending supplementation is lacking. The primary aim of this paper is to focus on the main open questions regarding vitamin D supplementation in CKD, reporting the current evidence concerning the role of vitamin D supplementation in CKD and in renal transplant recipients. Graphical abstract

24 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
APAnna Maria Pisacreta
Anna Maria Pisacreta
PMPaolo Molinari
Paolo Molinari
LCLara Caldiroli
Lara Caldiroli
MNMargherita Di Naro
Margherita Di Naro
FPFrancesco Pesce
Francesco Pesce
CACarlo Alfieri
Carlo Alfieri
Sarcopenia, defined as the progressive loss of skeletal muscle mass and strength, is increasingly recognized as a significant concern in patients with chronic kidney disease (CKD) and particularly in kidney transplant recipients (KTx-ps). This review explores the complex interplay of pathophysiological mechanisms, prevalence, and management strategies of sarcopenia in the context of kidney transplantation. CKD contributes to sarcopenia through systemic inflammation, malnutrition, uremic toxin accumulation, and metabolic imbalances, all of which persist or are exacerbated after transplantation due to immunosuppressive therapies especially corticosteroids. Notably, the post-transplant period may introduce additional risks, such as altered body composition and reduced physical activity, further aggravating muscle wasting. Sarcopenia affects approximately 26% of KTx-ps, leading to adverse outcomes including decreased quality of life, increased risk of infection, frailty, delayed recovery, and graft loss. The diagnosis remains challenging due to variability in assessment tools and a lack of standardized criteria. Management strategies must be multifactorial, including personalized nutritional support, targeted physical activity, and, where appropriate, pharmacological interventions. Early identification through imaging and functional testing is critical, especially in older patients and those with prolonged dialysis vintage. Emerging therapies, such as myostatin inhibitors, offer promise but require further validation. Additionally, early steroid withdrawal may mitigate muscle loss without compromising graft survival in selected patients. This review underscores the need for heightened awareness and standardized protocols to identify and manage sarcopenia in kidney transplantation, ultimately improving long-term outcomes and patient-centered care.

1 March 2026 in Journal Of Nephrology
Verified
Journal Article
Closed access
DMDeborah Mattinzoli
Deborah Mattinzoli
PMPaolo Molinari
Paolo Molinari
IMIkehata Masami
Ikehata Masami
FEFrancesca Marta Elli
Francesca Marta Elli
GSGiulia Del Sindaco
Giulia Del Sindaco
CACarlo Alfieri
Carlo Alfieri

13 January 2026 in Giornale di Clinica Nefrologica e Dialisi
Verified
Journal Article
Open access
AAAnna De Amici
Anna De Amici
CLChiara De Liso
Chiara De Liso
APAnna Maria Pisacreta
Anna Maria Pisacreta
MNMargherita Di Naro
Margherita Di Naro
LCLara Caldiroli
Lara Caldiroli
CACarlo Alfieri
Carlo Alfieri
Anemia is one of the most common complications in patients undergoing kidney transplantation, with an estimated prevalence between 30% and 50%, especially in the first six months after transplantation. The pathogenesis of anemia in these patients is multifactorial, related to chronic inflammation, disorders of iron metabolism, myelosuppression from several immunosuppressive drugs, and hormonal and metabolic alterations. The clinical implications of anemia in kidney transplants are significant: it is a negative prognostic factor for patient and transplant survival, significantly affecting cardiovascular risk and quality of life. This review analyzes in detail the pathogenic mechanisms of anemia in the post-transplant context, illustrating their clinical impact and providing an updated overview of currently available therapeutic strategies, with a focus on new molecules belonging to the class of prolyl-hydroxylase inhibitors (HIF-PHi), which are revolutionizing the therapeutic approach to anemia secondary to renal failure.